Analysts Compare Boston Scientific and Sysmex on Financial Metrics
1 report, 1 independent
Updated Oct 1
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Analysts compared Boston Scientific and Sysmex Corporation based on several financial indicators, including profitability, valuation, and risk. The comparison found that Boston Scientific has higher revenue and earnings than Sysmex. Furthermore, Boston Scientific trades at a lower price-to-earnings ratio and has a lower beta, suggesting less stock price volatility compared to Sysmex.
From themarketsdaily.com
Why it matters
The comparison provides insight into the relative investment profiles of the two healthcare companies. Boston Scientific's lower price-to-earnings ratio and lower volatility suggest a different risk and valuation profile compared to Sysmex.
From themarketsdaily.com
Who's involved
- Boston ScientificWorldwide developer, manufacturer, and marketer of medical devices
Keep exploring
The entities involved
-
Boston Scientific
worldwide developer, manufacturer and marketer of medical devices
- Corporate restructuring news includes the transformation of CORDIS from a division of Cardinal Health, the acquisitions of Guidant by Boston Scientific and Abbott Laboratories, and appointments involving Cirtec Medical.
- Joseph Fitzgerald was appointed executive vice president and president of MedSurg and Asia Pacific at Boston Scientific.